- Patient Education
Patient Education: Lenalidomide - Immunomodulatory Agents - IMIDS
Updated: Apr 8
Patient Education: Revlimid (lenalidomide) - Immunomodulatory Agents - IMIDS
LENALIDOMIDE (REVLIMID)
NIH National cancer institute -cancer.gov site info on Lenalidomide
This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s): Revlimid
FDA Approved: Yes
MedlinePlus Information on Lenalidomide.
A lay language summary of important information about this drug that may include the following:
warnings about this drug,
what this drug is used for and how it is used,
what you should tell your doctor before using this drug,
what you should know about this drug before using it,
other drugs that may interact with this drug, and
possible side effects.
Information on Revlimid website
INTERNATIONAL MYELOMA FOUNDATION:
Understanding Revlimid (lenalidomide)
Understanding the VRd (Velcade, Revlimid, Dex) Regimen for Newly Diagnosed Myeloma
IMF Understanding Series
IMF Resource Library
Current FDA-Approved Medications for Multiple Myeloma Treatment
HEALTH TREE UNIVERSITY MYELOMA:
All About Revlimid (lenalidomide)
HealthTree University for Multiple Myeloma Lectures
Health Tree University Myeloma Videos
MULTIPLE MYELOMA RESERACH FOUNDATION:
Standard Treatments - Revlimid (lenalidomide)
MMRF Education Programs
MMRF Videos
References Revlimid:
FDA Label Prescribing Information (Revised 08/2021)
Drug Label Information at DAILYMED - NIH-National Library of Medicine
Other Resources
- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -
* Belantamab mafodotin (Withdrawn from United States market)